T. Rowe Price Associates’s Galectin Therapeutics GALT Stock Holding History

T. Rowe Price Associates’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$183K	Buy	+39,313	New	+$102K	﹤0.01%	3032

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

T. Rowe Price Associates's GALT Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Galectin Therapeutics (GALT) in Q2 2026: 39,313 shares worth $183K. The stake represents ﹤0.01% of the portfolio and ranks #3032 among its holdings.

98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

T. Rowe Price Associates held 39,313 shares of Galectin Therapeutics worth $183K as of Q2 2026.
Galectin Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
Galectin Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3032 holding.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.